Pharmaceuticals

Onpattro Market 2026–2030: Forecasting Business Opportunities Ahead

March 6, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the onpattro market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Onpattro Market expected to reach by 2030?

Historic growth can be ascribed to progress in RNA-based pharmaceutical development, a rise in hATTR amyloidosis diagnoses, regulatory approvals for gene-silencing treatments, the expansion of specialized infusion centers, and the clinical confirmation of patisiran’s effectiveness.

The projected growth throughout the forecast period can be attributed to the expansion of next-generation RNA therapeutics, increasing investments in rare disease pipelines, a growing focus on personalized medicine, the development of subcutaneous delivery alternatives, and the rising adoption of genetic screening programs.

Major trends anticipated in the forecast period include the increasing adoption of RNA interference therapies, a rising focus on rare genetic disease treatment, the expansion of precision gene silencing approaches, improved clinical outcomes in amyloidosis care, and the growing integration of advanced infusion therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20169&type=smp

What Drivers Are Driving Adoption Within The Onpattro Market?

The increasing occurrence of hereditary transthyretin-mediated amyloidosis is projected to drive the expansion of the onpattro market in the future. Hereditary transthyretin-mediated amyloidosis (hATTR) is a rare inherited condition characterized by mutated TTR proteins that create damaging accumulations, impacting both nerves and the heart. This growing prevalence of hereditary transthyretin-mediated amyloidosis stems from advancements in diagnostics, more widespread genetic testing, and heightened public awareness, leading to the identification of more patients. Onpattro serves as a treatment for hereditary transthyretin-mediated amyloidosis by deactivating the transthyretin (TTR) gene, thereby decreasing the synthesis of amyloid protein and averting organ impairment. As an illustration, information from February 2024 by Verywell Health, a US-based health information platform, indicates that hereditary transthyretin-mediated amyloidosis globally impacts between 5,500–38,500 individuals. U.S. projections show 104 to 3,847 cases of hereditary transthyretin-mediated amyloidosis with polyneuropathy, underscoring substantial underdiagnosis. Consequently, the increased prevalence of hereditary transthyretin-mediated amyloidosis is propelling the expansion of the onpattro market.

What Segments Are Included Within The Onpattro Market?

The onpattro market covered in this report is segmented –

1) By Clinical Indication: Hereditary Transthyretin-Mediated Amyloidosis, Wild-Type Transthyretin Amyloidosis, Other Transthyretin-Related Amyloidoses

2) By Distribution Channel: Direct Sales, Pharmacies, Online Pharmacies

3) By End User: Hospitals, Specialty Clinics, Home Healthcare Providers

Which Trends Are Expected To Influence The Onpattro Market In The Upcoming Years?

A primary trend within the onpattro market involves broadening the drug’s approved uses via supplemental drug applications, intending to optimize market reach and address a greater spectrum of patient requirements. These supplemental applications typically seek to expand a drug’s sanctioned uses, for example, by targeting novel indications, patient groups, or formulations, thereby increasing its therapeutic scope and market opportunities. As an illustration, in February 2023, Alnylam Pharmaceuticals, a US-based pharmaceutical firm, disclosed the acceptance of a Supplemental New Drug Application (sNDA) concerning ONPATTRO (patisiran). This particular treatment addresses cardiomyopathy linked to transthyretin amyloidosis (ATTR). ONPATTRO functions as an RNA interference (RNAi) therapeutic, specifically engineered to target the transthyretin (TTR) protein, which can abnormally accumulate in individuals with ATTR amyloidosis, causing serious complications like cardiomyopathy. The medication originally received approval in 2018 for treating polyneuropathy associated with hereditary ATTR amyloidosis. The recent sNDA submission drew upon findings from the Phase III APOLLO-B study, which indicated that patisiran substantially enhanced functional capacity and life quality in patients with cardiomyopathy when compared to a placebo.

Who Are The Prominent Global Companies Shaping The Onpattro Market Landscape?

Major companies operating in the onpattro market are Alnylam Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/onpattro-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Onpattro Market?

North America was the largest region in the onpattro market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onpattro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Onpattro Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20169&type=smp

Browse Through More Reports Similar to the Global Onpattro Market 2026, By The Business Research Company

Online Insurance Market Report 2026

https://www.thebusinessresearchcompany.com/report/online-insurance-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

On Demand Transportation Market Report 2026

https://www.thebusinessresearchcompany.com/report/on-demand-transportation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795